Aptevo reduces IRRs with mipletamig regimen
Aptevo successfully refined mipletamig's priming dose to reduce patient infusion reactions. This improves tolerability for frontline AML patients, strengthening the drug's profile for Phase 2 development.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed